Bitcoin traded near $68,000 as geopolitical tensions eased, while Ethereum saw a 3% rise. Major altcoins experienced mixed movements. Marke...

The National Stock Exchange (NSE) will admit Swiggy, Waaree Energies, Premier Energies, and Bajaj Holdings & Investment to its Futures & Op...

The NSE has raised the quantity freeze limit for Bank Nifty derivatives from 600 to 900, effective September 1. Freeze limits for other key...

Uday Kotak flagged structural flaws in Indian markets — warning against excessive money power, distorted liquidity, and volume-driven busin...

Nuvama shares: In a strongly worded 105-page interim order, the Securities and Exchange Board of India (SEBI) accused Jane Street and its a...

SEBI stated that Jane Street earned an estimated ₹36,500 crore in profits between January 2023 and March 2025, with ₹43,289 crore generated...

India's market regulator, SEBI, has barred Jane Street, a U.S. trading firm, from accessing the Indian securities market following an inves...

The Enforcement Directorate (ED) conducted multi-city raids in the Mahadev Online Book Betting APP case, seizing ₹3.29 Crore in cash and fr...

The NSE of India will include six new stocks in the Futures and Options segment from January 31, 2025. The stocks are Castrol India, Gland ...

Companies will lay down a framework for developing a system to restrict the trading by designated persons by freezing the permanent account...

NSE said futures and options contracts on these securities would be available for trading with effect from June 25.

As per the terms of the agreement, India Glycols will contribute its renewable Bio-EO derivative business to the JV, which includes a multi...

NSE said the futures and options contracts on these companies would be available from February 28.

Mark Mobius, of Templeton Asset Management, said another financial crisis is inevitable because causes of previous one haven't been resolve...

Wockhardt's numerous and often complex currency deals have become the trickiest issue, as the troubled pharma firm looks for a lifeline and...

The company has intensifed cost-cutting measures in 2009, attributing the move to an uncertain trading outlook for the next two years.

Investors will have to wait for the new derivative products that the capital market regulator approved in principle last week.